Last reviewed · How we verify
long-acting beta-agonists
Long-acting beta-agonists bind to beta-2 adrenergic receptors on airway smooth muscle to cause sustained bronchodilation and improve airflow.
Long-acting beta-agonists bind to beta-2 adrenergic receptors on airway smooth muscle to cause sustained bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | long-acting beta-agonists |
|---|---|
| Sponsor | Genentech, Inc. |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
LABAs activate beta-2 adrenergic receptors, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation in the airways. This produces a prolonged bronchodilatory effect lasting 12-24 hours, making them suitable for maintenance therapy in chronic respiratory diseases. They are typically combined with inhaled corticosteroids to reduce exacerbations and improve lung function.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Nervousness or anxiety
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
- Bronchodilator Response in COPD and Asthma: Correlation Between Spirometry, IOS Indices, and Dyspnea Relief
- Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) (PHASE2)
- A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma (PHASE1)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Characteristics of Pts Initiating Spiriva Respimat in Asthma
- ICS+LABA Vs. ICS+LABA+Omalizumab: Impact on Asthma Control and Gene Expression (PHASE4)
- Appropriate Inhaler Use of Tiotropium As Add-on Therapy in Symptomatic Asthma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |